The genes for tumor necrosis factor (TNF-ALPHA) and lymphotoxin (TNF-BETA) are tandemly arranged on chromosome 17 of the mouse

Nucleic Acids Research (Impact Factor: 9.11). 10/1986; 14(19):7713-25. DOI: 10.1093/nar/14.19.7713
Source: OAI


We have isolated clones containing the gene for tumor necrosis factor (TNF-alpha) from a mouse genomic library. Four out of
five clones containing the TNF-alpha gene also hybridized to a human lymphotoxin (TNF-beta) probe. We constructed a restriction
enzyme cleavage map of a 6.4 kb region from one of the genomic clones. From partial sequencing data and hybridizations with
exon-specific oligonucleotide probes, we conclude that this region contains the mouse TNF-alpha and TNF-beta genes in a tandem
arrangement, that they are separated by only about 1100 bases, and that their intron-exon structure is very similar to that
seen in man. We probed genomic blots of DNA from human/mouse hybrids containing single mouse chromosomes for the presence
of the mouse TNF genes. The results show that the genes are located on mouse chromosome 17, which also contains the major
histocompatibi1ity complex. Therefore, both the mouse and the human TNF genes are tandemly arranged and located on the same
chromosome as the MHC.

Download full-text


Available from: Roberto S Accolla,
  • Source
    • "2. The TNF family and the genetic mouse models TNF is the founder member of cytokine TNF-like superfamily [5]. TNF gene is tightly linked with lymphotoxin (LT) a and b genes to the major histocompatibility locus on murine chromosome 17 (human 6), while the receptors (R), TNF-R1 and LTbR are clustered on mouse chromosome 6 and human chromosome 13 [6] [7]. Soluble homotrimeric TNF and lymphotoxin (LT)a bind either TNF-R1 (p55) or TNF-R2 (p75), while the membrane bound LTab heteromer engages LTb receptor. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor necrosis factor (TNF) is critical and non-redundant to control Mycobacterium tuberculosis infection and cannot be replaced by other proinflammatory cytokines. Overproduction of TNF may cause immunopathology, while TNF neutralization reactivates latent and chronic, controlled infection, which is relevant for the use of neutralizing TNF therapies in patients with rheumatoid arthritis.
    Microbes and Infection 05/2007; 9(5):623-8. DOI:10.1016/j.micinf.2007.02.002 · 2.86 Impact Factor
  • Source
    • "The interleukin-10 family of ligands Many cytokines exist within structurally related families. This is well-recognized in the case of the tumour necrosis factor (TNF) family of ligands, which comprises three adjacent, closely related genes within the MHC region on chromosome 6 [22] and several other genes on a variety of chromosomes, which continue to be uncovered. More recently, the Tcell-derived cytokine IL-17 was shown to be the prototype for a new family of cytokines which so far comprises IL-17A to IL-17E [23] [24]; a further example is to be found in the IL-1 family. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin-19 (IL-19) is a newly discovered member of the IL-10 family of ligands whose function is presently undefined. We recently described its cloning and initial characterization and in so doing, noted that the induction of IL-19 by LPS in human monocytes was down-regulated by interferon-gamma (IFN-gamma) and up-regulated by IL-4. This preliminary observation led us to speculate that IL-19 may play a role in the Th1/Th2 system and we examined this hypothesis further. Our results suggested that IL-19 is able to influence the maturation of human T-cells. CD4+ T-cells resulting from SEB stimulation in the presence of IL-19 contained a higher proportion of IL-4 producing cells than those developing in the absence of IL-19. This observation was complimented by the observation that fewer IFN-gamma cells accrued in the presence of IL-19, thereby suggesting that IL-19 altered the balance of Th1/Th2 cells in favour of Th2. Furthermore, in whole PBMC cultures, IL-19 up-regulated IL-4 and down-regulated IFNgamma in a dose-dependent manner. These results are presented here in review format, in the context of an overall discussion of IL-19 and its receptor.
    International Immunopharmacology 06/2004; 4(5):615-26. DOI:10.1016/j.intimp.2004.01.005 · 2.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Preeclampsia (PE) is a disease of late pregnancy characterized by maternal hypertension and proteinuria. It is associated with preterm delivery and significant perinatal morbidity and mortality. Despite affecting ~7% of first pregnancies, there is no effective screening method to identify women at risk, nor is there a definitive treatment other than delivery of the baby and placenta. Though the pathogenesis of PE remains unclear, an imbalance in the renin-angiotensin and immune systems are thought to be major contributors. Bridging these two concepts, it has recently been shown that women with PE harbor specific autoantibodies: the angiotensin II type 1 receptor activating autoantibody (AT1-AA). These autoantibodies act as angiotensin II and stimulate the ubiquitous AT1 receptor.To elucidate the role of AT1-AA in the pathophysiology of PE, a model of adoptive transfer was generated wherein AT1-AA isolated from human sera are injected into pregnant mice. This autoantibody incites the key features of the disease in pregnant mice: increased blood pressure, proteinuria, renal and placental abnormalities and increases in the anti-angiogenic factors soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin (sEng). These experiments were also carried out in non-pregnant animals who did not share the same symptoms. This suggests that pregnancy is a requirement for the full spectrum of preeclamptic features. In addition, the placentas and fetuses of AT1-AA-injected mice are reduced in size. The pups demonstrated intrauterine growth restriction (IUGR) and organ immaturity, especially in their kidneys and livers. To elucidate the mechanism by which these preeclamptic symptoms arise in the mouse model, the effects of increased inflammation were investigated. A multi-analyte screen indicated that the autoantibody induced inflammatory cytokines. TNF-alpha, a potent pro-apoptotic cytokine, known to be increased in both the sera and placentas of preeclamptic women, was most elevated, and was therefore the focus of further research. When incubated with AT1-AA, human placental explants greatly increased their production of TNF-alpha. In addition, TNF-alpha-mediated apoptosis was increased due to AT1-receptor activation in both the mouse placenta and human villous explants. Autoantibody-induced apoptosis and TNF-alpha production could be specifically reduced by co-treatment of AT1-AA with an anti-TNF-alpha antibody, losartan (an AT1 receptor blocker) or an antibody-neutralizing peptide, 7-aa. In order to test the pathophysiologic relationship between AT1-AA and TNF-alpha in vivo, the established adoptive transfer mouse model was employed. Co-injection of AT1-AA and an anti-TNF-alpha antibody reduced the features of PE in pregnant mice, implying an important pathogenic role for this cytokine.Overall, when injected into pregnant mice, AT1-AA induces the clinical features of PE and results in increased TNF-alpha production, placental apoptosis and fetal anomalies. Blockade of these features can be partially diminished by anti-TNF-alpha treatment, an AT1 receptor blocking drug, or a peptide which specifically neutralizes autoantibody action. Significantly, these findings could lead to a screening tool for preeclampsia as well as a potential therapeutic strategy for this life-threatening disease of mother and child.
Show more